INFI - Infinity Pharmaceuticals, Inc.
| Previous close | 0.1542 |
| Open | 0.1590 |
| Bid | 0.1595 x 1100 |
| Ask | 0.1600 x 800 |
| Day's range | 0.1501 - 0.1600 |
| 52-week range | 0.1200 - 1.7600 |
| Volume | |
| Avg. volume | 880,549 |
| Market cap | 14.385M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4900 |
| Earnings date | 05 Jun 2023 - 20 Jun 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.15 |
Business WireInfinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
CAMBRIDGE, Mass., April 13, 2023--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced upcoming presentations including data on eganelisib by Infinity’s collaborator, Professor Judith A. Varner of the UCSD Moores Cancer Center, La Jolla, California, at the 2023 Annual Meeting of the American Association of Ca
ZacksInfinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireInfinity Pharmaceuticals Reports Full Year 2022 Financial Results
CAMBRIDGE, Mass., March 28, 2023--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2022 financial results. The Company previously announced on February 23, 2023 its execution of a definitive merger agreement with MEI Pharma for a strategic combination of Infinity and MEI, which is expected t
ZacksWill Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
SAN DIEGO, CA. & CAMBRIDGE, Mass., February 23, 2023--MEI Pharma, Inc. (Nasdaq: MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies entered into a definitive merger agreement for an all-stock transaction form
Simply Wall St.The past five years for Infinity Pharmaceuticals (NASDAQ:INFI) investors has not been profitable
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
Business WireInfinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., November 22, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.
ZacksDown 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Simply Wall St.
Infinity Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations
Infinity Pharmaceuticals ( NASDAQ:INFI ) Third Quarter 2022 Results Key Financial Results Net loss: US$10.7m (flat on...
ZacksInfinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of -140% and 91.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireInfinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., November 14, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provided a business update, and in a separate press release provided more mature data from the Phase 2 MARIO-3 1L TNBC clinical trial.
Business WireInfinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
CAMBRIDGE, Mass., November 14, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple negative breast cancer (TNBC) patients.
Business WireInfinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., November 07, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022.
- Simply Wall St.
We're Keeping An Eye On Infinity Pharmaceuticals' (NASDAQ:INFI) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- Simply Wall St.
Investors in Infinity Pharmaceuticals (NASDAQ:INFI) have unfortunately lost 58% over the last year
It is doubtless a positive to see that the Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) share price has gained some...
Business WireInfinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
CAMBRIDGE, Mass., August 31, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference.
- Simply Wall St.
How Many Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Shares Do Institutions Own?
Every investor in Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) should be aware of the most powerful shareholder...
ZacksInfinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 1.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireInfinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., August 09, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2022 financial results, unveiled new positive data from the Phase 2 MARIO-275 clinical trial, and provided a business update.
Business WireInfinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., August 02, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022.